Pharmaceutical enterprises making innovation faster and more relevant

As biopharmaceuticals are a "strategically emerging industry "in China, the M Lab "will not only serve as a hub for the cultivation of industry talent but also accelerate the integration of China's life science value chain as well as promote cross border interaction and collaboration", said Chen Deming, chairman of the China Association of Enterprises with Foreign Investment.

The lab is also ambitious on the digital front. It adopts algorithms in research analytics and adopts visual recognition technologies to identify and label lab objects in an attempt to make scientific research more accurate and efficient.

"We create a smart monitoring system by … integrating cameras with AO (analog output) technologies in research labs so that they relieve researchers from staying on-site all the time, given that many experiments can require days (to complete)," Vermant said.

Also embracing digital technologies is French pharmaceutical giant Sanofi. Through a program that banks on external partnerships and ecosystems in China, the company aims to tap into promising start-ups on digital health initiatives.

During a celebration event earlier this month, Pius S. Hornstein, general manager of general medicines and country chair of Sanofi China, referred to the digital revolution as a "major opportunity to multinational pharmaceutical companies in China", and pledged that the company will team up with Chinese startups to jointly develop digital healthcare projects.

For instance, Sanofi is working with Atman, an AI start-up focused on smart medical language to build a bilingual intelligent medical information platform called Hippo.

Atman CEO Ma Lei said the platform serves as a one-stop solution for medical data monitoring, informatization extraction as well as processing, analysis and generation of medical reports.

"It can support evidence-based formulation of medical strategies, accelerate digital transformation of pharmaceutical companies and eventually help expand user scope," Ma said.

In another example of streamlined online physician consultation processes, which conventionally involve redundant works such as answering repeated questions, Sanofi joined hands with start-up firm Emotibots, which is known for its research in emotional computing.

"Our joint invention leads to a new online consultation platform that equips doctors with auto-reply functions and turns spoken language into structured language for AI to understand in real time and give a response, which saves a lot of trouble for physicians," said Jerry Gao, an innovation manager of internet hospitals at Sanofi China.

Ted Lai, chief digital officer at Sanofi China, believes China will lead the world in digital healthcare in a couple of years thanks to a combination of factors, including strong government support, a very robust innovative ecosystem of startups and big tech companies, the availability of patient data and the rollout of its 5G infrastructure.

Merck's Vermant said agile policy adjustment in China offers fast-track access to research materials that were previously unavailable. "This definitely serves the academy and makes innovation faster."